Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists
AbstractSince its discovery, the thrombopoietin (TPO) pathway has been an important pharmaceutical target for the treatment of thrombocytopenia. The first generation of TPO mimetics included peptide agents sharing homology with endogenous TPO, but these introduced a risk of antibody formation to endogenous TPO and were not successful. However, second-generation TPO mimetics or TPO receptor agonists (RAs) are currently being used to treat thrombocytopenia associated with a number of conditions, such as immune thrombocytopenia (ITP), severe aplastic anaemia (SAA), and hepatitis C virus-associated chronic liver disease. Accumulating efficacy and safety data suggest that the role of TPO-RAs in the treatment of thrombocytopenia may evolve in the near future with broader use of these agents in ITP and SAA, as well as approval in other indications, potentially including myelodysplastic syndromes, chemotherapy-associated thrombocytopenia, and post-transplant thrombocytopenia. This review provides an overview of clinical data on the efficacy and safety of TPO-RAs, emphasising recent findings that may expand their clinical utility.
Dr. Michael Dunn, who has been treating many of his patients for more than 20 years, provides HIV and hepatitis care in Tampa Bay.
Fetal MRI brain scans can advance the detection of abnormalities due to severe...Read more on AuntMinnie.comRelated Reading: Fetal MRI can spot early brain abnormality MRI shows maternal depression meds affect babies' brains 3T MRI fetal scans should not affect newborns' hearing Gadolinium in fetuses almost entirely cleared via placenta MRI links blood flow to brain development in preterm babies
Scientists have discovered a new way in which bacteria residing in the human gut may be able to contribute to chemotherapy resistance.
Are oncologists recommending less chemotherapy for early breast cancer?Journal of the National Cancer Institute
This study was designed to investigate the underlying molecular mechanisms of exenatide therapy on NAFLD. We used in vivo and in vitro techniques to investigate the protective effects of exenatide on fatty liver via fat mass and obesity associated gene (FTO) in a high-fat (HF) diet-induced NAFLD animal model and related cell culture model. Exenatide significantly decreased body weight, serum glucose, insulin, insulin resistance, serum free fatty acid, triglyceride, total cholesterol, low-density lipoprotein, aspartate aminotransferase, and alanine aminotransferase levels in HF-induced obese rabbits. Histological analysis s...
Aman Chauhan, MBBS, University of Kentucky shares Launching Phase 2 Trial In Multi-Center Fashion | Currently Evaluated in Bone Marrow Transplantation at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018
Aman Chauhan, MBBS, University of Kentucky shares Data Showed Diarrhea From Chemotherapy at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018
Conclusion: This study showed that from 166 samples most of them were in a chronic phase of HBV infection and just 5.4% of asymptomatic blood donors were in the acute phase or acute chronic phase of HBV infection. The major risk factor for HBV infection was a familial history of HBV. PMID: 29922420 [PubMed]
Conclusion: Prevalence of GDH was 23.8% (157/660) by ELFA. Toxin prevalence was 9.7% (64/660). Detection rates of C. difficile associated diarrhoea (CDAD) increased with inclusion of NAAT testing by ELFA. PMID: 29922412 [PubMed]
In conclusion, euphol exerted in vitro and i n vivo cytotoxicity against glioma cells, through several cancer pathways, including the activation of autophagy-associated cell death. These findings provide experimental support for further development of euphol as a novel therapeutic agent for GBM, either alone or in combination chemotherapy.